Altimmune Inc.’s stock (ALT) continues to rise above its goal

At the time of writing, Altimmune Inc. [ALT] stock is trading at $13.35, up up 5.20%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ALT shares have lost -7.23% over the last week, with a monthly amount drifted -27.56%, and not seem to be holding up well over a long-time horizon.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


On 14, September 2022, Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD. In a post published today on Yahoo Finance, All 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions in liver fat, with a 68.5% relative reduction in liver fat content in subjects receiving 1.8 mg dose at 12 weeks of treatment.

From an analyst’s perspective:

Previously, H.C. Wainwright started tracking the stock with Buy rating on June 02, 2021, and set its price target to $35. On February 11, 2021, Guggenheim initiated with a Buy rating and assigned a price target of $36 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $25 on December 14, 2020. B. Riley Securities reiterated its recommendation of a Buy and reduced its price target to $28 on November 12, 2020. B. Riley FBR started tracking with a Buy rating for this stock on September 25, 2020, and assigned it a price target of $31. In a note dated August 14, 2020, Evercore ISI initiated an Outperform rating.

For the past year, the stock price of Altimmune Inc. fluctuated between $3.83 and $23.49. Currently, Wall Street analysts expect the stock to reach $29.14 within the next 12 months. Altimmune Inc. [NASDAQ: ALT] shares were valued at $13.35 at the most recent close of the market. An investor can expect a potential return of 118.28% based on the average price forecast.

Analyzing the ALT fundamentals

According to Altimmune Inc. [NASDAQ:ALT], the company’s sales were 8.0 million in the recent quarter, which represents an -94.20% plunge. Gross Margin for this corporation currently stands at +87.50% with Operating Margin at -1937.35%, Pretax Margin comes in at -2201.43%, and Net Margin reading is -2201.43%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.63 points at the first support level, and at 11.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.78, and for the 2nd resistance point, it is at 14.22.

Altimmune Inc. [ALT] reported earnings per share of -$0.44 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.58/share, meaning a difference of $0.14 and a surprise factor of 24.10%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.57 per share as compared to estimates of -$0.65 per share, a difference of $0.08 representing a surprise of 12.30%.

Ratios To Look Out For

It is important to note that Altimmune Inc. [NASDAQ:ALT] has a current ratio of 14.10. Also, the Quick Ratio is 11.17, while the Cash Ratio stands at 10.41. Considering the valuation of this stock, the price to sales ratio is 85.74, the price to book ratio is 1.89.

Transactions by insiders

We now turn our attention to insider trading, which in the past 3 months has resulted in 10 insider buyings of 91,367 shares and 8 insider sellings of 118,602 shares. Recent insider trading involved Garg Vipin K, President and CEO, that happened on Aug 31 when 20000.0 shares were sold. President and CEO, Garg Vipin K completed a deal on Aug 12 to sell 15000.0 shares. Meanwhile, Chief Scientific Officer Roberts M Scot sold 10182.0 shares on Jul 05.